HSP90 inhibitors showed promising results in ameliorating experimental uveitis through the inhibition of NFκB, hypoxia induced factor (HIF)-1α, p38, and phosphatidylinositol 3-Kinase (PI3K) activity, and a reduction in vascular endothelial growth factor (VEGF), TNF-α, and IL-1β levels [38,39,40]. This evidence concerns the gene VEGFA and uveitis.